Connect your AI

HTFL HTFL Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Boston ScientificBSX

——

Other financials

Income statement

Revenue$52.6M+41.3%

Gross profit$42.2M+50.9%

Operating income-$29.5M-68.6%

Net income-$27.4M+15.4%

EPS (diluted)-$0.32+93.9%

Balance sheet

Cash & equivalents$24.4M-78.7%

Total debt$26.3M—

Total equity$285.7M+132%

Total assets$344.0M—

Cash flow

Operating cash flow-$30.1M-129%

CapEx$1.9M+71.6%

Free cash flow-$32.0M-124%

Valuation

Market cap$2.97B—

Enterprise value$2.98B—

P/S15.5×—

Profitability

Gross margin78.1%+2.4pp

Operating margin-39.7%-4.8pp

Net margin-58.4%-12.1pp

FCF margin-40.1%-2.4pp

Returns & leverage

Return on equity37.1%—

Debt / equity0.1×—

Current ratio5.6×—

Where this comes from

Reported directly by HTFL in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: HTFL’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about HTFL's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is HTFL's indefinite-lived research and development assets?: HTFL (HTFL) reported indefinite-lived research and development assets of $15.41M in Q4 2025.
What does indefinite-lived research and development assets mean?: Represents the value of acquired in-process research and development projects that are not yet subject to amortization because they have not reached commercial viability. These assets are tested for impairment annually rather than being amortized over a fixed period. This metric reflects the company's investment in long-term innovation and future product pipelines.